<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335268</url>
  </required_header>
  <id_info>
    <org_study_id>440/47 EUROPE</org_study_id>
    <nct_id>NCT02335268</nct_id>
  </id_info>
  <brief_title>VALIDATION OF A PREDICTIVE MODEL OF RESPONSE TO ROMIPLOSTIM IN PATIENTS WITH IPSS LOW OR INTERMEDIATE-1 RISK MDS AND THROMBOCYTOPENIA</brief_title>
  <acronym>EUROPE</acronym>
  <official_title>PROSPECTIVE VALIDATION OF A PREDICTIVE MODEL OF RESPONSE TO ROMIPLOSTIM IN PATIENTS WITH IPSS LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME (MDS) AND THROMBOCYTOPENIA - THE EUROPE-TRIAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are currently no licensed drugs in the EU to treat thrombocytopenia in MDS patients&#xD;
      classified as IPSS low/int-1. Prior studies with romiplostim (a TPO receptor agonist) in MDS&#xD;
      found that baseline concentration of TPO as well as transfusion history were predictive of&#xD;
      subsequent response in a retrospective model. The current prospective study has the aim to&#xD;
      explore whether both pretreatment variables (endogenous TPO, TPO-level, platelet transfusion&#xD;
      history) can predict the response to subsequent short-term treatment with romiplostim.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic malignancies of the&#xD;
      pluripotent hematopoietic stem cells characterized by clonal hematopoiesis, progressive bone&#xD;
      marrow failure, and the propensity to transform to acute myeloid leukemia (AML) (Malcovati et&#xD;
      al., 2013).&#xD;
&#xD;
      There are currently no licensed drugs in the EU to treat thrombocytopenia in MDS patients&#xD;
      classified as IPSS low/int-1. Prior studies with romiplostim (a TPO receptor agonist) in MDS&#xD;
      found that baseline concentration of TPO as well as transfusion history were predictive of&#xD;
      subsequent response in a retrospective model.&#xD;
&#xD;
      Classically, MDS is associated with apoptosis and excessive proliferation, resulting in a&#xD;
      combination of a hyper-cellular marrow and peripheral cytopenia. The rationale for using&#xD;
      romiplostim in MDS is to stimulate normal progenitor cells to increase platelet counts. Upon&#xD;
      correction of thrombocytopenia, responding MDS patients should have a decreased risk of&#xD;
      bleeding and a reduction in platelet transfusions (Giagounidis et al., 2014). This reduction&#xD;
      in platelet transfusions may in turn decrease the risks of alloimmunization and the resultant&#xD;
      morbidity and costs associated with that condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2015</start_date>
  <completion_date type="Actual">May 20, 2021</completion_date>
  <primary_completion_date type="Actual">August 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematologic improvement of platelets (HI-P) after 4 months on therapy</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative hematologic improvement of platelets (HI-P), erythrocytes (HI-E) and neutrophils (HI-N)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of disease progression to higher stage MDS or AML</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase of peripheral blasts during therapy</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of the presence of certain mutations with disease progression in a retrospective analysis</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of bleeding events</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type, incidence and severity of all adverse events including clinically significant changes in laboratory values</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stratification into group 1 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are +3&#xD;
TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stratification into group 2 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are -1 or -2&#xD;
TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stratification into group 3 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are -6&#xD;
TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Plate / romiplostim</intervention_name>
    <description>medical intervention in 3 patient groups (MDS patients with IPSS Low/Int-1) that are stratified according to their baseline TPO-Level and previous transfusions</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must meet the following inclusion/exclusion criteria to be eligible for the&#xD;
             study.&#xD;
&#xD;
          -  Must understand and voluntarily sign the informed consent form&#xD;
&#xD;
          -  Age older 18 years at the time of signing the informed consent form&#xD;
&#xD;
          -  Must be able to adhere to the study visit schedule and other protocol requirements&#xD;
&#xD;
          -  Diagnosis of MDS using the 2008 WHO classification for myeloid neoplasms as assessed&#xD;
             during the screening period&#xD;
&#xD;
          -  Per MDS IPSS, low or intermediate-1 risk MDS as assessed during the screening period&#xD;
&#xD;
          -  The mean of the 2 platelet counts taken within 4 weeks prior to stratification must&#xD;
             be:&#xD;
&#xD;
          -  ≤ 30 x 109/L (with no individual count &gt; 30 x 109/L during the screening period), with&#xD;
             or without a history of bleeding associated with the diagnosis of MDS, OR&#xD;
&#xD;
          -  &lt; 50 x 109/L (with no individual count &gt;60 x 109/L during the screening period), with&#xD;
             a history of bleeding associated with the diagnosis of MDS (A standard of care&#xD;
             platelet count taken prior to Informed consent may be used as 1 of the 2 counts taken&#xD;
             within 4 weeks prior to stratification)&#xD;
&#xD;
          -  Adequate liver function, as evidenced by ALT ≤ 3 times the laboratory normal range,&#xD;
             AST ≤ 3 times the laboratory normal range and total bilirubin ≤ 2 times the laboratory&#xD;
             normal range&#xD;
&#xD;
          -  Bone marrow aspirate (central diagnostics) with cytogenetics (local) within 8 weeks of&#xD;
             starting first dose of investigational product&#xD;
&#xD;
          -  Female subjects of childbearing potential† must:&#xD;
&#xD;
          -  Agree to use, and be able to comply with, effective contraception without&#xD;
             interruption, 4 weeks before starting study drug, throughout study drug therapy and&#xD;
             for 4 weeks after the end of study drug therapy, even if she has amenorrhoea. This&#xD;
             applies unless the subject commits to absolute and continued abstinence confirmed on a&#xD;
             monthly basis. Male patients who wish to participate in the study and their partner&#xD;
             may become pregnant must agree also to reliable contraception during the study and for&#xD;
             three months thereafter.&#xD;
&#xD;
        The following are effective methods of contraception*&#xD;
&#xD;
          -  Implant, - Levonorgestrel-releasing intrauterine system (IUS), Medroxyprogesterone&#xD;
             acetate depot, Tubal sterilization, Sexual intercourse with a vasectomised male&#xD;
             partner only; Ovulation inhibitory progesterone-only pills (i.e., desogestrel)&#xD;
&#xD;
          -  Agree to have a medically supervised pregnancy test with a minimum sensitivity of 25&#xD;
             mIU/ml not more than 3 days before the start of study medication once the subject has&#xD;
             been on effective contraception for at least 4 weeks. This requirement also applies to&#xD;
             women of childbearing potential who practice complete and continued abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  IPSS intermediate-2 or high-risk&#xD;
&#xD;
          -  ≥ 5% blasts in the bone marrow as determined by central morphology during screening&#xD;
&#xD;
          -  Previous treatment with any thrombopoietic growth factor&#xD;
&#xD;
          -  Prior history of hematopoietic stem cell transplantation, leukemia, aplastic anemia or&#xD;
             other non-MDS related bone marrow stem cell disorder&#xD;
&#xD;
          -  Active or uncontrolled disease including infections or cancer&#xD;
&#xD;
          -  Unstable angina, congestive heart failure (NYHA &gt; class II), uncontrolled hypertension&#xD;
&#xD;
          -  History of arterial thrombosis (e.g., stroke or transient ischemic attack) within the&#xD;
             past year&#xD;
&#xD;
          -  History of venous thrombosis that currently requires anti-coagulation therapy&#xD;
&#xD;
          -  Prior use of sc or iv AZA.&#xD;
&#xD;
          -  Receipt of G-CSF, peg-G-CSF, or GM-CSF,IL-11, ESA or LEN within 4 weeks of the first&#xD;
             dose of romiplostim&#xD;
&#xD;
          -  Planned receipt of peg-G-CSF or GM-CSF after the first dose of investigational product&#xD;
&#xD;
          -  Subjects of reproductive potential who are not using adequate contraceptive&#xD;
             precautions, in the judgment of the investigator. A double barrier method is defined&#xD;
             as 2 methods of contraception, for example 2 actual barrier methods, or 1 actual&#xD;
             barrier method and 1 hormonal method.&#xD;
&#xD;
          -  Known hypersensitivity to any recombinant E. coli-derived product (eg, Nplate,&#xD;
             Infergen, Neupogen, Somatropin, and Actimmune)&#xD;
&#xD;
          -  Inability to comply with study procedures.&#xD;
&#xD;
          -  Subject currently is enrolled in or has not yet completed at least 30 days since&#xD;
             ending other investigational device or drug study(s)&#xD;
&#xD;
          -  Any serious medical condition or psychiatric illness that will prevent the subject&#xD;
             from signing the informed consent form or will place the subject at unacceptable risk&#xD;
             if he/she participates in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Platzbecker, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University of Dresden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lionel Ades, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Groupe Francophone des Myelodysplasies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Haut Lévèque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Lyon sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPC</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Meaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Beausoleil</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Le Languedoc</name>
      <address>
        <city>Narbonne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Onkologischer Schwerpunkt am Oskar-Helene-Heim</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum am Urban / Hämatologie Onkologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH / Klinik für Innere Medizin III</name>
      <address>
        <city>Chemnitz</city>
        <zip>09116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden / Medizinische Klinik I</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Düsseldorf GmbH / Innere Medizin u. Hämatologie</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale) / Klinik für Innere Medizin IV</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf /Onkologisches Zentrum</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover / Hämatologie u. Onkologie</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim / Klinik III / Hämatologie, Onkologie</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar, Tumortherapiezentrum</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ für Blut u. Krebserkrankungen</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm / Klinik Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Weilheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rems-Murr-Kliniken Winnenden / Hämatologie, Onkologie</name>
      <address>
        <city>Winnenden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 7, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2015</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS classified as IPSS low/int-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

